Warner Chilcott plc
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY12 | FY11 | FY10 | FY09 | FY08 | |
|---|---|---|---|---|---|
| Revenue | $685.0M | $757.0M | $2.97B | $1.44B | $938.1M |
| Operating income | — | $650.1M | $643.0M | $712.0M | — |
| Net income | $113.0M | −$24.0M | $171.0M | $514.1M | −$8.4M |
| Total assets | $4.22B | $5.03B | $5.65B | $6.05B | — |
| Total liabilities | $4.82B | $4.96B | $5.72B | $4.17B | — |
| Equity | −$600.0M | $69.0M | −$66.0M | $1.89B | $1.35B |
| EPS (diluted) | $0.45 | $-0.10 | $0.67 | $2.05 | $-0.03 |
| Shares out. | 249.3M | 252.6M | 252.5M | 251.6M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2012- Operating margin
- —
- Net margin
- 16.5%
- Return on equity
- −18.8%
- Return on assets
- 2.7%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 114.2%
- Debt / equity
- —
- Book value / share
- $-2.41
- Revenue growth (YoY)
- −9.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2012- Accruals / assets
- −18.6%clean
- Beneish M-Score
- -3.68normal
- Piotroski F-Score
- 7/8strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 2 warning● 2 good- Negative shareholder equity
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- ACTONEL WITH CALCIUM (COPACKAGED)Aug 12, 2005
- FEMHRTOct 15, 1999
- LORAZEPAMJan 12, 1988
- VERAPAMIL HYDROCHLORIDEAug 20, 1986
- DORYXOct 30, 1985
- ORLEX HCMar 3, 1980
- ORLEXOct 26, 1979
- CYCLOPARAug 29, 1978
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Howson Tamar DDirector | Sep 30, 2013 | D | 4,170 | — |
| Fenton AndrewOfficer — Senior V.P., CIO | Sep 30, 2013 | D | 15,470 | — |
| Fuhrmann RochelleOfficer — Senior V.P., Finance | Sep 30, 2013 | D | 15,470 | — |
| Cross Leland HOfficer — Senior V.P. | Sep 30, 2013 | D | 15,470 | — |
| Gilligan Claire AOfficer — Senior V.P., Quality | Sep 30, 2013 | D | 15,470 | — |
| Ellman HermanOfficer — Senior V.P., Clinical Devel. | Sep 30, 2013 | D | 15,470 | — |
| Boissonneault Roger MOfficer — CEO & President | Sep 30, 2013 | D | 117,120 | — |
| Halstead MichaelOfficer — Senior V.P., Corp. Development | Sep 30, 2013 | D | 15,470 | — |
| Herendeen PaulOfficer — Exec. V.P. and CFO | Sep 30, 2013 | D | 37,720 | — |
| Howard Alvin DOfficer — Sr. V.P., Regulatory Affairs | Sep 30, 2013 | D | 15,470 | — |
| Bloem James HDirector | Sep 30, 2013 | D | 4,170 | — |
| King John ADirector | Sep 30, 2013 | D | 4,170 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · New financial obligation · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer changeOct 3, 2013
- Shareholder vote · Other material eventSep 10, 2013
- Other material eventSep 4, 2013
- Other material eventAug 29, 2013
- Other material eventAug 22, 2013
- Other material eventAug 9, 2013
- Regulation FD disclosureAug 2, 2013
- Other material eventAug 1, 2013
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 11, 2014
- 15-12GFORM 15Oct 11, 2013
- 8-KFORM 8-KOct 3, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
- 4PRIMARY DOCUMENTOct 1, 2013
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.